In light of the economic downturn, USA-based Hollis-Eden Pharmaceuticals has implemented an aggressive cost-cutting plan in order to preserve capital.
The firm is to focus its resources on advancing the Triolex (HE3286) and Apoptone (HE3235) development programs. To achieve this, Hollis-Eden will reduce its workforce by around 33%, or 20 employees, as well as freeze salaries and suspend bonuses for all remaining staff, including executive officers. The firm believes that, as it had no outstanding debts, this will allow it to operate without reliance on equity markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze